We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

73 hedge funds and large institutions have $217M invested in BioCryst Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 17 increasing their positions, 20 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

755% more capital invested

Capital invested by funds: $25.4M → $217M (+$192M)

67% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 15

64% more call options, than puts

Call options by funds: $4.96M | Put options by funds: $3.02M

16% more funds holding

Funds holding: 63 → 73 (+10)

15% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 20

Holders
73
Holders Change
+10
Holders Change %
+15.87%
% of All Funds
2.37%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.06%
New
25
Increased
17
Reduced
20
Closed
15
Calls
$4.96M
Puts
$3.02M
Net Calls
+$1.94M
Net Calls Change
+$1.99M

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$29.6M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$13.3M
3
DM
Deerfield Management
New York
+$8.28M
4
VM
VHCP Management
New York
+$5.92M
5
BBA
Baker Bros. Advisors
New York
+$5.76M

Top Sellers

Rank Fund Capital Flow
1
Northern Trust
Northern Trust
Illinois
-$1.99M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.65M
3
TC
TFS Capital
Pennsylvania
-$1.13M
4
Deutsche Bank
Deutsche Bank
Germany
-$917K
5
Barclays
Barclays
United Kingdom
-$726K
Name Holding Trade Value Shares
Change 		Change in
Stake
Connor, Clark & Lunn Investment Management (CC&L)
76
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
– -$183K -111,800 Closed
CCMH
77
Cornerstone Capital Management Holdings
New York
– -$160K -102,600 Closed
Jacobs Levy Equity Management
78
Jacobs Levy Equity Management
New Jersey
– -$109K -70,400 Closed
State Board of Administration of Florida Retirement System
79
State Board of Administration of Florida Retirement System
Florida
– -$62K -40,133 Closed
JP Morgan Chase
80
JP Morgan Chase
New York
– -$61K -39,595 Closed
ProShare Advisors
81
ProShare Advisors
Maryland
– -$54K -34,599 Closed
Citadel Advisors
82
Citadel Advisors
Florida
– -$152K -29,974 Closed
NFA
83
Nationwide Fund Advisors
Ohio
– -$34K -22,090 Closed
SG Americas Securities
84
SG Americas Securities
New York
– -$34K -21,870 Closed
CAS
85
CTC Alternative Strategies
Illinois
– -$18.4K -11,900 Closed
PAM
86
Paradigm Asset Management
New York
– -$17.4K -11,200 Closed
AllianceBernstein
87
AllianceBernstein
Tennessee
– -$14K -9,136 Closed
TCIM
88
TIAA CREF Investment Management
New York
– -$8K -4,886 Closed
1 2 3
4

BCRX Hedge Fund Activity: Q3 2013 in Review

73 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q3 2013, worth a combined $217M — up 755% from $25.4M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new BCRX positions and 15 closed out — a net gain of 10 holders — while 17 added to existing stakes and 20 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $29.6M. The largest seller was Northern Trust, cutting an estimated $1.99M.

  • 73 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q3 2013, up from 63 in Q2 2013.
  • Funds reported $217M of BioCryst Pharmaceuticals stock for Q3 2013, up 755% quarter-over-quarter.
  • 25 funds opened new BioCryst Pharmaceuticals positions in Q3 2013 and 15 closed out, a net change of +10 holders.
  • The largest BioCryst Pharmaceuticals buyer in Q3 2013 was RA Capital Management, an estimated $29.6M added.
  • The largest BioCryst Pharmaceuticals seller in Q3 2013 was Northern Trust, an estimated $1.99M sold.

Based on aggregated 13F filings for Q3 2013.